# A Phase I Study of CDX-622

> **NCT06650761** · PHASE1 · COMPLETED · sponsor: **Celldex Therapeutics** · enrollment: 85 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** CDX-622
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT06650761
- **Lead sponsor:** Celldex Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-11-01
- **Primary completion:** 2026-04-24
- **Final completion:** 2026-04-24
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06650761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06650761, "A Phase I Study of CDX-622". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06650761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*